Sarcopenia Treatment: What Actually Rebuilds Strength

What is the treatment for sarcopenia?

Resistance exercise plus enough protein — in that order of importance, and together rather than separately. Everything else in sarcopenia treatment is either supportive or still experimental.

That sounds almost too simple for a condition the European consensus classes as a muscle disease. But the EWGSOP2 consensus is direct about the mechanism: while genetic and lifestyle factors hasten muscle weakening, "interventions including nutrition and exercise training seem to slow or reverse these processes". Cruz-Jentoft et al., Age and Ageing, 2019 The same paper notes that sarcopenia "has been overlooked and undertreated in mainstream practice" — which is the real problem. If you are unsure whether the label applies to you, start with what sarcopenia actually is.

Is there a drug for sarcopenia?

No. Nothing is licensed for it. A 2026 review of the pharmacological pipeline in Annals of Translational Medicine states that "There are currently no specific drugs approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of sarcopenia." Yang et al., Annals of Translational Medicine, 2026

Plenty is in development — selective androgen receptor modulators, myostatin antibodies, ghrelin agonists. The same review flags why none has crossed the line yet: "while several candidates increase muscle mass, few consistently improve muscle strength or physical function, reflecting a disconnect between surrogate endpoints and clinically meaningful outcomes."

Does resistance training actually rebuild muscle if you already have sarcopenia?

It reliably rebuilds strength and function. Muscle size is far less certain. A 2026 systematic review and meta-analysis pooled twelve randomised trials in 518 older women with sarcopenia and found resistance training significantly improved grip strength (SMD 0.43), gait speed (SMD 0.37), knee extension strength (SMD 0.85), Timed Up and Go (SMD −0.68) and the 30-second chair stand (SMD 0.52) — but had no significant effect on skeletal muscle mass index. Zhou et al., Frontiers in Public Health, 2026

This is not a disappointing result. Strength and gait speed are the measures most closely tied to staying mobile and independent — and they are exactly what the scales cannot tell you. The British Geriatrics Society's themed collection on sarcopenia puts it plainly, reporting a 2004 systematic review: "resistance training had clear evidence of a beneficial effect in sarcopenia." British Geriatrics Society / Age and Ageing, 2019 The same page is candid that "there have been relatively few randomised controlled trials to treat sarcopenia" — the evidence base is real but thinner than the condition deserves.

The mechanism is the one described in our guide to resistance training for bone density: muscle pulls on bone, and both adapt to the demand placed on them.

How much protein do you actually need?

At least 1.0 to 1.2 g per kg of body weight per day if you are a healthy older adult — more if you are unwell. The ESPEN Expert Group's recommendation is specific: "for healthy older people, the diet should provide at least 1.0–1.2 g protein/kg body weight/day", and "for older people who are malnourished or at risk of malnutrition because they have acute or chronic illness, the diet should provide 1.2–1.5 g protein/kg body weight/day". Deutz et al., Clinical Nutrition, 2014

Body weight	Healthy older adult (1.0–1.2 g/kg)	Illness or malnutrition risk (1.2–1.5 g/kg)
55 kg	55–66 g/day	66–83 g/day
70 kg	70–84 g/day	84–105 g/day
85 kg	85–102 g/day	102–128 g/day

The same ESPEN recommendation pairs it with movement: "daily physical activity or exercise (resistance training, aerobic exercise) should be undertaken by all older people, for as long as possible." Protein without load, and load without protein, both underperform the combination. For how protein sits alongside calcium and vitamin D for the skeleton as well as the muscle, see vitamin D, calcium and protein for bone health.

What does an effective programme look like in practice?

Structured, supervised, progressive, and at least twice a week. Two reference points are useful here — one clinical guidance, one a large trial.

The NHS advises adults aged 65 and over to do "activities that improve strength, balance and flexibility on at least 2 days a week" alongside "at least 150 minutes of moderate intensity activity a week", and notes that to get benefit from strength exercises "you should do them to the point where you need a short rest before repeating the activity." NHS, physical activity guidelines for older adults

The SPRINTT trial went further, and is the best test yet of treating sarcopenia as a target in its own right. Across 16 sites in 11 European countries, 1,519 community-dwelling adults aged 70 and over with physical frailty and sarcopenia were randomised to a multicomponent programme — moderate-intensity physical activity twice weekly at a centre and up to four times weekly at home, plus personalised nutritional counselling — or to healthy-ageing education. Among those with a short physical performance battery score of 3 to 7, mobility disability occurred in 46.8% of the intervention group versus 52.7% of controls (hazard ratio 0.78, 95% CI 0.67 to 0.92). Physical performance improved by 0.8 SPPB points at 24 months and 1.0 point at 36 months in the programme's favour. Bernabei et al., The BMJ, 2022

One honest caveat: among participants who started in better shape, with SPPB scores of 8 or 9, no benefit was shown (hazard ratio 1.25, 95% CI 0.79 to 1.95). SPRINTT supports treating people who are already struggling; it does not prove the same programme changes outcomes for everyone.

Why do UK sarcopenia programmes so often under-deliver?

Because the prescription usually stops progressing. The Benchmarking Exercise Programmes for Older People (BEPOP) project, a joint British Geriatrics Society and AGILE initiative, collected real practice data from ten UK services treating people with probable sarcopenia or frailty. Its findings are uncomfortable reading: surveys had already found resistance exercise was "offered in only 9% of departments and was often not optimised for sarcopenia and frailty", and within programmes that did offer it, exercise advanced "predominantly through increased repetitions (n=163, 87%) rather than increased load." BGS and AGILE, BEPOP project

Worse for anyone hoping to know whether their treatment worked: 41 patients (24%) had no review to inform progression of their exercise dose, and 50 patients (30%) had no re-assessment of the outcome measures recorded at baseline when their programme finished.

The patient's lesson is short: ask what the progression plan is, and ask when you will be re-measured.

How do you tell whether treatment is working?

Re-measure the thing that identified the problem. EWGSOP2 gives usable numbers: low grip strength is under 27 kg for men and under 16 kg for women, and a chair-stand time of over 15 seconds for five rises counts as low strength. Gait speed of 0.8 m/s or slower marks low physical performance. Repeating those simple tests after a training block is the cheapest honest feedback available — and grip strength doubles as a marker worth tracking for fracture risk.

Because muscle and bone decline together, a change in one is often a warning about the other; that overlap is what osteosarcopenia describes, and it is why strength work also belongs in a falls-prevention plan. If you want an objective baseline of bone alongside the muscle picture, a bone health assessment gives you a number to measure change against rather than a guess.